CPLX2, complexin 2, 10814

N. diseases: 22; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE For both mRNA and protein, the complexin II/complexin I ratio was lower in schizophrenia, confirming the relatively greater loss of the excitatory marker. 9853440 1998
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 AlteredExpression disease BEFREE As dysfunction in synaptic transmission plays a key role in schizophrenia, and complexin2 (CPLX2) gene expression is reduced in hippocampus of schizophrenic patients, we developed a mouse model with Cplx2 null mutation as genetic risk factor and a mild parietal neurotrauma, applied during puberty, as environmental 'second hit'. 20412316 2010
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE We measured the expression of three synaptic proteins (synaptophysin, complexin I and complexin II) in the cerebellar cortex of 16 subjects with schizophrenia and 16 controls using in situ hybridisation histochemistry and immunoautoradiography. 11483314 2001
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 GeneticVariation disease BEFREE Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. 20819981 2010
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE In this in situ hybridization histochemistry (ISHH) study, we examined four informative synaptic protein transcripts: vesicular glutamate transporter (VGLUT) 1, VGLUT2, complexin I, and complexin II, in dorsolateral prefrontal cortex (DPFC), superior temporal cortex (STC), and hippocampal formation, in 13 subjects with schizophrenia and 18 controls. 15653259 2005
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE We conducted a genetic association analysis between complexin genes (CPLX1 and CPLX2) and schizophrenia in Japanese patients (377 cases and 341 controls). 16442780 2006
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE No significant changes in complexin 1, VGAT, complexin 2, VGluT1, dysbindin, NAV2, or VAMP1 mRNA expression were found; however, expression of mRNAs associated with plasticity/cytoskeletal modification (GAP43 and NAV1) was reduced in schizophrenia. 21145444 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 GeneticVariation disease BEFREE Since increased working memory-related neural activity in individuals with or at risk for schizophrenia has been interpreted as 'neural inefficiency,' these findings suggest that certain variants of CPLX2 may contribute to impaired brain function in schizophrenia, possibly combined with other deleterious genetic variants, adverse environmental events, or developmental insults. 25297695 2015
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.310 AlteredExpression disease BEFREE Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression. 20584925 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.310 AlteredExpression disease BEFREE Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression. 20584925 2010
CUI: C1263846
Disease: Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder 		0.110 GeneticVariation disease BEFREE We also detected rare inherited CNVs in 19 of 248 (7.7%) ADHD probands, which were absent in 2357 controls and which either overlapped previously implicated ADHD loci (for example, DRD5 and 15q13 microduplication) or identified new candidate susceptibility genes (ASTN2, CPLX2, ZBBX, and PTPRN2). 21832240 2011
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.030 Biomarker disease BEFREE Presynaptic proteins complexin-I and complexin-II differentially influence cognitive function in early and late stages of Alzheimer's disease. 27866231 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.030 Biomarker disease BEFREE The functional analysis on the differentially expressed proteins suggested that complexin-1 and complexin-2 may be the key molecules involved in chronic copper exposure-aggravated memory impairment in AD. 25352456 2015
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.030 AlteredExpression disease BEFREE Semi-quantitative analysis of immunohistochemical staining confirmed decreased levels of complexin-1, complexin-2 and synaptogyrin-1 in the outer two-thirds of the molecular layer of the dentate gyrus in AD. 31699905 2020
CUI: C0020179
Disease: Huntington Disease
Huntington Disease 		0.010 Biomarker disease BEFREE Complexin 2 is a protein modulator of neurotransmitter release that is downregulated in humans suffering from depression, animal models of depression and neurological disorders such as Huntington's disease in which depression is a major symptom. 20584925 2010
CUI: C0027765
Disease: nervous system disorder
nervous system disorder 		0.010 Biomarker group BEFREE Complexin 2 is a protein modulator of neurotransmitter release that is downregulated in humans suffering from depression, animal models of depression and neurological disorders such as Huntington's disease in which depression is a major symptom. 20584925 2010
CUI: C0221505
Disease: Lesion of brain
Lesion of brain 		0.010 GeneticVariation group BEFREE Correspondingly, in Cplx2 -null mutant mice, prominent cognitive loss of function was obtained only in combination with a minor brain lesion applied during puberty, modeling a clinically relevant environmental risk ("second hit") for schizophrenia. 20819981 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.010 Biomarker phenotype BEFREE The functional analysis on the differentially expressed proteins suggested that complexin-1 and complexin-2 may be the key molecules involved in chronic copper exposure-aggravated memory impairment in AD. 25352456 2015
CUI: C0338656
Disease: Impaired cognition
Impaired cognition 		0.010 GeneticVariation disease BEFREE Previous studies found common variants in the complexin2 (CPLX2) gene to be highly associated with cognitive dysfunction in schizophrenia patients. 25297695 2015
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.010 AlteredExpression phenotype BEFREE Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression. 20584925 2010
CUI: C0542476
Disease: Forgetful
Forgetful 		0.010 Biomarker phenotype BEFREE The functional analysis on the differentially expressed proteins suggested that complexin-1 and complexin-2 may be the key molecules involved in chronic copper exposure-aggravated memory impairment in AD. 25352456 2015
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease CTD_human In schizophrenia, synaptophysin mRNA was decreased, as was complexin II and its mRNA. 11483314 2001
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0005587
Disease: Depression, Bipolar
Depression, Bipolar 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004